Clinical Trials

Title

A Phase 3, Randomized, Double-blind, Placebo-controlled, Event-driven Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor Xia Inhibitor, After a Recent Acute Coronary Syndrome

• Short Title LIBREXIA-ACS
• Category Cardiology: Electro-Physiology
• Status Recruiting

Diagnosis

Acute Coronary Syndrome

Participating Locations

Erlanger

Principal Investigator

Harish Manyam, MD

Contact

• Name Erlanger Institute for Clinical Research
• Phone 4237783900
• Email [email protected]